Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GEB - Genetronics Biomedical -- Ignore unavailable to you. Want to Upgrade?

To: Dan Hamilton who wrote (2)	4/25/1999 12:07:00 AM
From: MAX LLOYD	Read Replies (1) \| Respond to of 31

Genetronics has revenue through it's BTX devision but it's big revenue will come through it's comprehensive world wide marketing agreement with Ethicon, a Johnson & Johnson company. Final European clinical trials are to be announced along with final U.S. phase II clinical trials in May and the results are supposed to be amazing.... European sales should start by 4th. Quarter 1999. Look for U.S. phase III trials to start this summer........ My target $8.00 U.S. per share ! by October 1999....